NAD+ (injectable)
naturally occurring coenzyme (a dinucleotide, not a peptide)
Also called: Body Protection Compound 157, pentadecapeptide BPC 157, PL 14736, bepecin
BPC-157 is a lab-made 15-amino-acid peptide whose sequence comes from a larger protein isolated from human stomach juice. It has been studied mainly by one research group in Croatia, almost entirely in rats and cell cultures.
It is the best-known 'healing peptide' in gym culture, with a reputation for helping tendons, ligaments and the gut, and it is often paired with TB-500 in what people call the 'Wolverine stack'. That reputation rests far more on animal studies and anecdotes than on human trials.
Human evidence: very limited. No randomized controlled trial in humans has been published; what exists is an uncontrolled chart-review survey and a 2-person safety pilot.
S0 Non-Approved Substances. BPC-157 is named in S0 on the 2026 list, so it is prohibited at all times, in and out of competition.
High. A positive test is a violation. FDA's compounding changes do not affect WADA status. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved. FDA placed BPC-157 in Category 2 (significant safety risks) of the interim 503A bulks list in 2023. On April 15, 2026 FDA removed it and 11 other peptides from Category 2, but removal did not make them eligible for 503A compounding. FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) on July 23, 2026 to recommend BPC-157 for the 503A bulks list. That vote is non-binding, and as of Oct 1, 2026 no proposed rule or final decision has been found, so BPC-157 is not yet on the 503A bulks list. In late August 2026 FDA also issued warning letters to online peptide sellers, treating their products as unapproved new drugs.
As of 2026-10-01.
S0 Non-Approved Substances. BPC-157 is named in S0 on the 2026 list, so it is prohibited at all times, in and out of competition. High. A positive test is a violation. FDA's compounding changes do not affect WADA status. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved. FDA placed BPC-157 in Category 2 (significant safety risks) of the interim 503A bulks list in 2023. On April 15, 2026 FDA removed it and 11 other peptides from Category 2, but removal did not make them eligible for 503A compounding. FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) on July 23, 2026 to recommend BPC-157 for the 503A bulks list. That vote is non-binding, and as of Oct 1, 2026 no proposed rule or final decision has been found, so BPC-157 is not yet on the 503A bulks list. In late August 2026 FDA also issued warning letters to online peptide sellers, treating their products as unapproved new drugs.
Very limited. No randomized controlled trial in humans has been published; what exists is an uncontrolled chart-review survey and a 2-person safety pilot.
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
naturally occurring coenzyme (a dinucleotide, not a peptide)
synthetic peptide based on thymosin beta-4, an actin-binding protein found in most cells